Eli Lilly & Co. (LLY) Announces FDA Approval of Kisunla to Treat Early Symptomatic Alzheimer's Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. JNJ
3. AAPL
4. META
5. NVDA
6. AMAT
7. NRIX
8. SPY
9. OIG
10. BAC

Go back to Eli Lilly & Co. (LLY) Announces FDA Approval of Kisunla to Treat Early Symptomatic Alzheimer's Disease

Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease

July 2, 2024 1:35 PM EDT

Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants' risk of progressing to the next clinical stage of disease by up to 39% 

Kisunla is the first and only amyloid plaque-targeting therapy that used a limited-duration treatment regimen based on amyloid plaque removal; nearly half of study participants completed their course of treatment with Kisunla in 12 months

Once-monthly infusions of 30 minutes reduced amyloid plaques on average by 84% compared to the start of the... More